
FOCIS 2026 Annual Meeting
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to FOCIS 2026 Annual Meeting — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
FOCIS 2026 — Event Buyer Intelligence & Attendee List Research Overview
Event Title: FOCIS 2026
Event Type: Immunology, Clinical Research, Translational Medicine, Biotechnology, Pharma, Medical Science, Academic Research Conference
Best Use Case: Deep research for attendee list selling, buyer targeting, event intelligence, and account selection for life sciences, biotech, pharma, diagnostics, research tools, and medical education products.
FOCIS 2026 is a high-value scientific and medical meeting for the immunology and translational medicine ecosystem. The event typically attracts a concentrated audience of researchers, clinicians, pharma and biotech professionals, lab leaders, academic investigators, and solution providers working in immune-related science. For attendee-list research, this is not a general consumer event; it is a specialized B2B and scientific decision-maker environment where the most valuable contacts are usually senior researchers, heads of labs, medical directors, translational scientists, product development leaders, and business development professionals from life sciences companies.
1️⃣ Who attends: Buyers / Attendees
FOCIS-style meetings usually attract a very targeted scientific audience. The strongest attendee groups are people who influence research purchasing, protocol design, clinical studies, assay selection, diagnostics adoption, therapeutic development, and scientific collaboration. The attendee base is usually composed of both academic and commercial stakeholders, which makes the event useful for companies selling research tools, reagents, instruments, software, CRO services, diagnostics, lab automation, and scientific services.
Main attendee groups:
- Immunologists, translational scientists, and principal investigators
- Clinical researchers and physician-scientists
- Pharma and biotech R&D leaders
- Medical affairs professionals
- Lab directors and research directors
- Director-level and VP-level life sciences decision-makers
- Postdoctoral researchers, fellows, and graduate scientists
- Diagnostic company representatives
- Research tool and reagent vendors
- Biomarker, assay, and platform specialists
- Immunotherapy and vaccine development professionals
- University faculty and hospital-based research teams
The key difference here is that attendees are not just “scientific spectators.” Many of them directly influence buying decisions for lab equipment, consumables, data platforms, services, and partnership opportunities. That is why FOCIS 2026 can be a strong source for both attendee list research and account-based lead targeting.
2️⃣ Where the show is happening + attendee geographic origin
Show location: FOCIS 2026 will likely take place in a major U.S. conference destination, as the meeting generally rotates through large convention or hotel-based venues. The exact venue should be verified from the official event website once you share the client product context or target region.
Attendee geographic origin: FOCIS is typically a global scientific meeting with strong participation from the United States, Canada, Europe, the United Kingdom, Asia, and other research-intensive regions. The attendee base is often international because immunology and translational medicine are highly collaborative global fields.
Best geographic targeting:
- United States national audience
- High concentration from major biotech and research hubs such as Boston, San Diego, San Francisco Bay Area, New York, Philadelphia, Raleigh-Durham, Houston, and Seattle
- International attendees from Europe, the UK, Canada, Israel, Japan, South Korea, Singapore, and Australia
- Strong academic and hospital research presence from major medical centers worldwide
3️⃣ Audience reach
Reach type: Global with strong U.S. concentration
FOCIS 2026 should be viewed as a global scientific conference rather than a purely local or national event. It has international relevance because immunology research, biologics development, cell therapy, vaccine science, and translational medicine depend on worldwide collaboration. The practical buyer pool, however, is still strongest among U.S.-based and North American institutions, with meaningful participation from leading global research organizations.
4️⃣ Sample buyer company names + websites
Below is a sample list of strong buyer accounts that can be useful for attendee list targeting or account-based outreach. These are organizations likely to attend, sponsor, exhibit, partner, or purchase products and services in the immunology and life sciences ecosystem.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Pfizer | pfizer.com | Director, Immunology R&D / Medical Director / Clinical Development Lead | Strong immunology and vaccine development presence; highly relevant to translational and clinical science buyers. |
| 2 | Merck & Co. | merck.com | Senior Scientist / Clinical Research Director / Translational Medicine Lead | Major biopharma buyer with interest in immune science, clinical studies, and research partnerships. |
| 3 | Roche | roche.com | Global Medical Affairs Manager / Biomarker Lead / Diagnostics Partnership Manager | Excellent fit for diagnostics, biomarkers, and precision medicine engagement. |
| 4 | Novartis | novartis.com | Head of Immunology Research / Clinical Program Lead | Relevant for immunology pipelines, clinical collaboration, and scientific innovation. |
| 5 | GSK | gsk.com | Vaccine R&D Director / Scientific Affairs Manager | Strong buyer for immunology, vaccines, and scientific engagement. |
| 6 | Sanofi | sanofi.com | Medical Science Liaison / Immunology Program Lead | Highly relevant to immune-mediated disease and biologics research. |
| 7 | AbbVie | abbvie.com | Director, Immunology Franchise / Research Scientist | Very strong match for immunology-focused scientific content and clinical decision-makers. |
| 8 | Bristol Myers Squibb | bms.com | Translational Medicine Director / Clinical Development Manager | Good fit for immune-oncology, translational research, and advanced therapeutics. |
| 9 | Regeneron | regeneron.com | Principal Scientist / R&D Program Manager | Strong science-led company with major focus on biologics and immune-related research. |
| 10 | Amgen | amgen.com | Research Director / Scientific Affairs Lead | Relevant for biotech innovation, immunology, and targeted therapy development. |
| 11 | Thermo Fisher Scientific | thermofisher.com | Product Marketing Manager / Life Sciences Sales Director | Excellent buyer for instruments, reagents, lab tools, and scientific workflow solutions. |
| 12 | Bio-Rad Laboratories | bio-rad.com | Business Development Manager / Product Manager, Immunoassays | Strong fit for assay platforms, diagnostics, and research products. |
| 13 | BD | bd.com | Clinical Diagnostics Manager / Research Collaboration Lead | Relevant for flow cytometry, diagnostics, and clinical research tools. |
| 14 | QIAGEN | qiagen.com | Product Manager, Molecular Diagnostics / Field Application Scientist | Good fit for molecular testing, immunology workflows, and research kits. |
| 15 | Sartorius | sartorius.com | Bioprocess Sales Manager / Lab Solutions Director | Relevant for bioprocessing, lab tools, and workflow optimization buyers. |
| 16 | Miltenyi Biotec | miltenyibiotec.com | Scientific Sales Manager / Immunology Product Specialist | Very strong fit for cell therapy, immune cell analysis, and research tools. |
| 17 | BD Biosciences | bdbiosciences.com | Marketing Manager / Flow Cytometry Product Specialist | Excellent for immunology researchers who use cell analysis and flow-based workflows. |
| 18 | AstraZeneca | astrazeneca.com | Immunology Portfolio Lead / Clinical Research Director | Relevant to immune-driven disease pipelines and global research collaborations. |
| 19 | Takeda | takeda.com | Medical Affairs Director / Research Partnerships Manager | Strong fit for rare disease, immunology, and biologics engagement. |
| 20 | Wuxi AppTec | wuxiapptec.com | Business Development Director / Scientific Services Lead | Very useful for CRO/CDMO buyer targeting and outsourcing-driven research support. |
Top 5 sample buyers to send first: Pfizer, Roche, Thermo Fisher Scientific, AbbVie, and Miltenyi Biotec. These companies represent a strong mix of pharma, diagnostics, lab tools, and immunology-specific buying potential.
5️⃣ Job profiles, industries & event type
FOCIS 2026 is a science-heavy event, so your best targets are not broad marketing contacts. The highest-value contacts are technical, clinical, and research decision-makers who influence purchases or partnerships.
Best job profiles to target:
- Director, Immunology Research
- Vice President, R&D
- Medical Director
- Clinical Development Director
- Translational Medicine Lead
- Principal Scientist
- Senior Scientist
- Lab Director
- Research Director
- Scientific Affairs Manager
- Biomarker Lead
- Medical Science Liaison
- Product Manager, Life Sciences
- Business Development Director
- Field Application Scientist
- Diagnostic Development Manager
- Regulatory Science Manager
- Clinical Research Manager
Best industries to use:
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Research
- Hospital & Health Care
- Biotechnology-adjacent scientific services
- Pharmaceutical manufacturing
- Information Services for scientific data platforms
- Medical Practice for physician-research audiences
- Higher Education
- Education Management
- Professional Training & Coaching for scientific education vendors
- Bioprocessing and lab services via keyword-based company filtering
- Market Research for healthcare intelligence companies
- Management Consulting for life sciences consultants
For best results, combine industry filters with job title filters and company keyword logic. Since this is a highly specialized conference, role-based targeting is more valuable than broad industry-only targeting.
6️⃣ Estimated attendance / expected footfall
Estimated attendance: Medium-sized, highly specialized scientific conference
FOCIS meetings typically do not draw mass-market footfall like consumer expos. Instead, they attract a focused, high-quality audience of researchers and industry professionals. Depending on the year, attendance can often be in the range of several hundred to a few thousand participants. Because exact 2026 registration data may not yet be fully public, the safest estimate is a concentrated professional audience with strong buyer quality rather than very large volume.
For attendee-list selling, the quality of the audience is more important than raw headcount. Even if the total attendance is modest compared with large trade shows, the percentage of decision-makers and scientifically relevant contacts is high.
7️⃣ Key focus areas & buyer engagement
Key focus areas:
- Immunology research
- Translational medicine
- Clinical immunology
- Inflammation and immune-mediated disease
- Biomarkers and diagnostics
- Cell therapy and immune-cell analysis
- Vaccine and infectious disease research
- Autoimmune disease
- Cancer immunology and immunotherapy
- Lab methods, assay development, and scientific platforms
- Research collaboration and partnering
- Medical education and scientific publishing
Buyer engagement angle: This event should be framed as a high-value immunology and translational science audience, not as a generic healthcare event. The best outreach message is centered on research intent, scientific collaboration, clinical decision-making, and product relevance.
Examples of high-converting positioning:
- Access to immunology researchers, translational scientists, and clinical development decision-makers
- Reach pharma and biotech teams working on biologics, vaccines, diagnostics, and immune therapies
- Connect with lab directors and research leaders evaluating scientific tools and services
- Engage academic and hospital-based investigators with direct influence over study design and purchasing
8️⃣ Client product fit note
To give you the best buyer list, I need your client website first. The correct target audience depends heavily on what your client sells.
Example matching logic:
- If the client sells lab instruments, consumables, or reagents, target research directors, lab managers, and product users in pharma, biotech, and academia.
- If the client sells software or data platforms, target clinical research leaders, translational medicine teams, informatics leaders, and R&D operations teams.
- If the client sells diagnostics, target biomarker leads, medical affairs, pathology-adjacent teams, and diagnostic development managers.
- If the client sells CRO/CDMO services, target biotech and pharma business development, outsourcing, and program management teams.
- If the client sells educational or publishing products, target faculty, investigators, training leads, and scientific communication teams.
Please share the client website, and I can refine the best buyers based on their exact product, service, and ideal customer profile.
9️⃣ Industry recommendation based on life sciences industry list
Based on your industry list, the best industry filters for FOCIS 2026 are:
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Hospital & Health Care
- Research
- Higher Education
- Education Management
- Professional Training & Coaching
- Information Services
- Management Consulting
- Market Research
- Medical Practice
If you want a more precise list, I would also layer in company keywords such as immunology, cell therapy, biomarkers, diagnostics, translational medicine, inflammatory disease, clinical research, vaccine, assay, and biologics.
Final recommendation
FOCIS 2026 is a strong event for attendee-list selling if your client targets life sciences, immunology, biotech, pharma, diagnostics, research tools, or scientific services. It is especially valuable because the audience is highly specialized and decision-maker dense.
Best buyer segments to collect:
- Pharma and biotech R&D leaders
- Immunology researchers and principal investigators
- Medical directors and clinical development teams
- Lab directors and scientific managers
- Diagnostics and biomarker leaders
- Scientific services and CRO/CDMO teams
- Research tool and reagent buyers
- Academic and hospital-based investigators
Quality rating for B2B attendee-list sales: 9/10
This is a highly relevant, specialized, and buyer-rich scientific event with strong conversion potential for the right product category. It becomes even more powerful once the client website is reviewed and the buyer profile is matched precisely.
Next step: Please send your client website, and I will review it and tell you the best buyers to target from FOCIS 2026.
Data sheet
| Event Name | FOCIS 2026 Annual Meeting |
| Event Date | June 9–12, 2026 |
| Event Status | Completed |
| Venue | San Francisco Marriott Marquis |
| City | San Francisco |
| State / Region | California |
| Country | United States |
| Organizer | Federation of Clinical Immunology Societies (FOCIS) – organizer name commonly associated with the annual meeting; current-edition organizer page should be verified from official event materials. |
| Official Event Website | Official current-edition event page not fully verified from the materials provided. |
| Event Type | Scientific conference / annual meeting focused on clinical immunology, translational medicine, biotechnology, pharma, and medical research collaboration. |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Education & Training |
| Audience Reach | National to international specialist scientific audience. |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer in the materials available for this review. |
| Attendance Data Reliability | Low for current-year numeric attendance; high for event identity, dates, and venue based on provided details. |
| Main Purpose of Event | To convene immunology researchers, physician-scientists, clinical investigators, biotech and pharma professionals, and supporting life-science solution providers for education, collaboration, translational research exchange, and scientific-commercial networking. |
FOCIS 2026 Annual Meeting is a specialized immunology and translational medicine conference environment rather than a broad consumer or general healthcare expo. The event is most relevant to academic medical centers, research hospitals, biotechnology companies, pharmaceutical R&D groups, clinical investigators, translational science teams, and suppliers serving immune-related discovery, diagnostics, therapeutic development, clinical studies, and laboratory operations.
From a commercial intelligence perspective, this meeting matters because it concentrates scientifically sophisticated decision influencers in a focused setting. The strongest lead value typically comes from principal investigators, lab directors, translational medicine leaders, medical affairs stakeholders, clinical development teams, research operations personnel, and business development or partnership leaders evaluating technologies, assays, platforms, collaborations, grants, publications, and trial-enablement solutions.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Academic investigators and principal investigators | Universities, medical schools, academic research institutes | Influence lab purchasing, assay selection, study design, collaboration decisions | High relevance for research tools, reagents, diagnostics, software, data platforms |
| Clinical immunologists and physician-scientists | Academic hospitals, specialty clinics, translational medicine centers | Influence biomarker adoption, clinical protocols, testing pathways, referral research | High relevance for diagnostics, clinical platforms, medical education, trial support |
| Biotech R&D and translational science leaders | Biotechnology firms, immunotherapy developers, platform companies | Evaluate enabling technologies, CROs, biomarkers, sample workflows, partnerships | Very strong fit for translational tools, bioinformatics, outsourcing, assay and platform vendors |
| Pharmaceutical clinical development teams | Large pharma and specialty therapeutics companies | Assess trial strategy, external scientific partnerships, biomarker programs | High relevance for CROs, CDMOs, trial technology, patient data, scientific services |
| Laboratory directors and core facility managers | Research institutes, hospitals, genomics/proteomics/immunology cores | Direct or influence purchasing of instruments, workflow systems, software, consumables | Very high relevance for lab suppliers and scientific equipment providers |
| Medical affairs and scientific communications teams | Biopharma, diagnostics, specialty medical organizations | Influence KOL engagement, congress strategy, evidence dissemination | Relevant for medical education, content services, publication support, event partnership |
| Clinical research operations and program managers | Academic centers, hospitals, sponsors, CROs | Operational buying influence for study execution, data capture, biosample logistics | High relevance for eClinical, logistics, site support, compliance tools |
| Business development and partnership leaders | Biotech, pharma, diagnostics, research service firms | Source collaborations, licensing, channel relationships, platform alliances | High relevance for strategic outreach and account-based selling |
| Scientific society and association leaders | Professional societies, foundations, nonprofit research groups | Influence education programs, sponsorship opportunities, member engagement | Moderate to high relevance for sponsorship, publishing, training, and engagement tools |
| Investors and innovation scouts | Life science investors, venture groups, strategic innovation teams | Evaluate pipelines, platforms, scientific teams, collaboration potential | Selective but valuable for partnership intelligence and market mapping |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| San Francisco | Local academic, biotech, and healthcare ecosystem participants | High | Strong local concentration of biotech firms, hospitals, investors, and research institutions |
| California | Bay Area, South San Francisco, Palo Alto, San Diego, Los Angeles research communities | Very High | California is a major life sciences and translational medicine hub |
| U.S. West Coast | Participants from Washington, Oregon, and western research centers | Medium to High | Convenient travel access improves scientific meeting participation |
| U.S. National | Academic medical centers, NIH-linked researchers, biotech and pharma teams nationwide | High | FOCIS is positioned as a specialist scientific meeting with national relevance |
| International | Likely attendance from Europe, Canada, and Asia-Pacific immunology communities | Medium | International scientific participation is likely, but current-year geographic mix is not publicly confirmed in the materials reviewed |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Primary Reach | National | The event serves a U.S.-wide specialist audience across academic medicine, biotech, pharma, and immunology research. |
| Secondary Reach | International specialist relevance | Immunology and translational medicine are globally networked fields, making international participation likely, though exact 2026 mix is not confirmed here. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| UCSF | Academic medical center | Major local immunology, translational, and clinical research presence in San Francisco | ucsf.edu | Principal Investigator, Lab Director, Clinical Research Director | Strong Market Fit, Attendance Not Confirmed |
| Stanford Medicine | Academic medical center | High-value translational and immunology research institution in the host region | stanfordmedicine.org | Professor of Medicine, Immunology Research Director, Core Facility Manager | Strong Market Fit, Attendance Not Confirmed |
| National Institutes of Health | Government research organization | Key U.S. immunology and clinical research stakeholder with broad scientific influence | nih.gov | Program Director, Scientific Review Officer, Clinical Investigator | Strong Market Fit, Attendance Not Confirmed |
| Genentech | Biopharma | Major Bay Area therapeutics player with immunology and translational research relevance | gene.com | Translational Medicine Director, Clinical Scientist, External Innovation Lead | Strong Market Fit, Attendance Not Confirmed |
| Gilead Sciences | Biopharma | Relevant for immune-mediated disease, clinical development, and biomarker-driven programs | gilead.com | Clinical Development Director, Biomarker Lead, Medical Affairs Director | Strong Market Fit, Attendance Not Confirmed |
| AbbVie | Pharmaceutical company | Strong immunology franchise and translational research interests | abbvie.com | Immunology Research Director, Medical Director, Alliance Manager | Strong Market Fit, Attendance Not Confirmed |
| Amgen | Biopharma | Relevant for inflammation, biologics, translational, and clinical immunology work | amgen.com | Scientific Director, Translational Sciences Lead, Clinical Program Lead | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Pharmaceutical company | Relevant for immune-oncology, translational science, and biomarker partnerships | bms.com | Clinical Scientist, Translational Medicine Director, Medical Affairs Leader | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Pharmaceutical company | Broad immunology and clinical research footprint | pfizer.com | Medical Director, Clinical Research Lead, External Partnerships Director | Strong Market Fit, Attendance Not Confirmed |
| Regeneron | Biotech / biopharma | Strong fit for immunology, biologics, and translational medicine ecosystems | regeneron.com | Translational Genetics Lead, Clinical Biomarker Lead, Research Collaborations Director | Strong Market Fit, Attendance Not Confirmed |
| Dana-Farber Cancer Institute | Research hospital | High relevance for immune-focused translational and clinical research | dana-farber.org | Physician-Scientist, Program Director, Lab Head | Strong Market Fit, Attendance Not Confirmed |
| Memorial Sloan Kettering Cancer Center | Research hospital | Relevant for immunotherapy, translational science, and biomarker innovation | mskcc.org | Immunology Investigator, Clinical Trials Director, Core Lab Director | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Principal Investigator | Research | Senior / Director | Drives study design, collaboration, platform selection, and grant-backed spending |
| 2 | Director of Translational Medicine | R&D / Clinical Development | Director / VP | Evaluates biomarkers, platforms, assays, and external scientific partnerships |
| 3 | Clinical Research Director | Clinical Research | Director | Influences site operations, clinical tools, workflows, and study execution vendors |
| 4 | Lab Director / Core Facility Director | Laboratory Operations | Director | Direct buyer or key influencer for instrumentation, software, consumables, and services |
| 5 | Medical Director | Medical Affairs / Clinical | Director | Important for diagnostics, evidence, educational partnerships, and therapeutic positioning |
| 6 | Scientific Director | Research / Innovation | Director | High influence over platform evaluation and scientific partnership decisions |
| 7 | Clinical Scientist | Clinical Development | Manager / Senior IC | Strong user-level evaluator for protocols, biomarkers, and study technologies |
| 8 | Procurement Manager, Research Operations | Procurement / Operations | Manager | Useful where enterprise or institutional contracts govern scientific purchasing |
| 9 | Business Development Director | Business Development / Partnerships | Director | Relevant for co-development, licensing, channel, and strategic alliance outreach |
| 10 | Director, Biomarkers / Translational Sciences | R&D | Director | Key role for assays, sample analytics, platform validation, and companion research tools |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core commercial audience for immunology and translational science | Platform partnerships, assays, translational tools, biomarker services |
| 2 | Pharmaceuticals | Strong fit for clinical development, immunology pipelines, and scientific collaborations | Clinical research support, biomarker solutions, KOL programs |
| 3 | Hospital & Health Care | Academic hospitals and research centers are key attendees | Clinical diagnostics, study operations, translational collaborations |
| 4 | Research | Research institutes and discovery organizations align strongly with event focus | Scientific tools, data analytics, grant-supported purchasing |
| 5 | Higher Education | Universities and medical schools supply investigators and lab buyers | Lab technology, scientific software, education and training products |
| 6 | Medical Devices | Relevant for diagnostics, instrumentation, and patient-monitoring solutions | Instrument placement, assay platforms, clinical device partnerships |
| 7 | Information Technology & Services | Relevant for data platforms, trial software, research informatics, interoperability | Scientific data systems, analytics, digital workflow tools |
| 8 | Computer Software | Applicable to bioinformatics, LIMS, collaboration, and scientific analytics providers | Research workflow automation and interpretation tools |
| 9 | Health, Wellness & Fitness | Selective fit for immune health education and patient-support adjacent programs | Education, engagement, and disease-awareness programs |
| 10 | Nonprofit Organization Management | Societies, foundations, and disease associations participate in scientific ecosystems | Sponsorship, education, registry, and advocacy partnerships |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer | Unconfirmed | No verified current-year attendance figure in the materials provided | Use caution for list-size assumptions |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Current exhibitor prospectus / floor list not available in provided materials | Likely modest to medium versus large expo-scale life-science shows |
| Buyer count | Not publicly confirmed | Unconfirmed | No verified buyer-only metric identified from supplied details | Scientific meetings rarely publish a distinct buyer count |
| Speaker count | Not publicly confirmed | Unconfirmed | Agenda detail not fully verified in current review | Speaker organizations would be valuable for high-fit account selection once confirmed |
| Sponsor count | Not publicly confirmed | Unconfirmed | No sponsor roster validated from supplied materials | Sponsor list would help identify active commercial solution providers |
| Historical attendance | Not established in this review | Historical / prior-year evidence unavailable | Requires official prior-year annual meeting materials | Recommended next step for list-building accuracy |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Immunology research | Access to assays, reagents, instruments, and validated workflows | Scientific demo meetings, poster-side discussions, investigator outreach | Research tools, antibodies, consumables, instrument platforms |
| Translational medicine | Bridge discovery research to patient-facing applications | Partnership-led selling to translational and biomarker teams | Biomarker solutions, translational analytics, clinical assay services |
| Clinical research | Site workflows, compliance, biosample management, protocol support | Meetings with clinical operations, investigators, and study managers | eClinical tools, logistics, CRO support, sample tracking |
| Diagnostics and biomarkers | Validation, sensitivity, reproducibility, translational application | KOL-driven adoption conversations and pilot-study positioning | Diagnostic platforms, biomarker panels, companion research services |
| Data and bioinformatics | Data integration, interpretation, reproducibility, reporting | Solution briefings for lab heads and translational science teams | Software, analytics, LIMS, collaboration tools |
| Therapeutic development | External innovation, disease-area expertise, platform access | BD and alliance meetings with biotech and pharma stakeholders | Research partnerships, CRO/CDMO support, scientific consulting |
| Medical education and publications | KOL visibility, evidence communication, education delivery | Outreach to medical affairs and society leadership | Medical communications, CME, publication support |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | The event aligns strongly with life sciences, clinical research, diagnostics, and scientific tool buyers or influencers. |
| Decision-maker availability | High | Specialist annual meetings attract senior investigators, medical leaders, and translational science decision influencers. |
| Data collection potential | Medium | Lead quality can be strong, but attendee-list availability may be limited unless sponsor, exhibitor, speaker, or abstract rosters are accessible. |
| Apollo targeting potential | Very High | The account universe is identifiable through industry, titles, therapeutic focus, and research-function filters. |
| Geographic targeting potential | High | Bay Area plus national academic and biopharma hubs create strong regional and national clustering. |
| Best outreach approach | High | Use account-based outreach with scientific relevance, publication context, biomarker/translational use cases, and meeting follow-up angles. |
| Overall lead quality | High | Strong quality for niche life-science and clinical research offers; lower value for broad non-scientific products. |
| Best use case | High-fit B2B scientific targeting | Best for buyer profiling, speaker/account mapping, life sciences outbound, and curated attendee-intelligence builds. |
| Limitations / risks | Medium | Current-year attendance counts and official participant lists were not confirmed in the materials available for this report. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Hospital & Health Care; Research; Higher Education; Medical Devices; Information Technology & Services; Computer Software; Nonprofit Organization Management | Build a high-fit event-alike account list |
| Departments | Research, Clinical, Medical Affairs, Operations, Procurement, Business Development, Partnerships, Innovation | Focus on scientific and commercial decision influencers |
| Seniority | Director, VP, Head, CXO, Partner, Professor, Principal, Senior Manager | Prioritize strategic buyers and high-authority scientific users |
| Job titles | Principal Investigator; Director of Translational Medicine; Clinical Research Director; Scientific Director; Medical Director; Lab Director; Biomarker Director; Clinical Scientist; Research Operations Manager; Business Development Director | Replicate the event's most valuable attendee roles |
| Geography | United States; California; Massachusetts; New York; Maryland; New Jersey; Pennsylvania; Texas; Washington; major biotech corridors | Target likely attendee-source geographies and leading life-science hubs |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Capture both emerging biotech firms and large biopharma / medical systems |
| Keywords | immunology, translational medicine, biomarker, inflammation, autoimmune, immune-oncology, clinical research, assay development, immunotherapy, cytokine, flow cytometry, single-cell | Narrow to event-relevant scientific domains |
| Technologies, if relevant | LIMS, ELN, bioinformatics, flow cytometry, sequencing, cloud analytics, clinical trial software | Useful for platform or software sellers |
| Revenue range, if relevant | Mid-market to enterprise for biopharma; selective smaller-revenue biotech targets for innovation-stage selling | Prioritize budgets aligned to scientific solution pricing |
| Company type | Public companies, private biotech, academic institutions, nonprofit research centers, teaching hospitals | Covers the event's cross-sector attendee profile |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-provided event details | Provided input | Event title, city, state, country, venue, and dates | High for the fields supplied by the requester |
| Federation of Clinical Immunology Societies (FOCIS) | Organizer website | Organizer identity and thematic relevance of the FOCIS scientific community | Medium; current-edition page should be checked for final confirmation |
| Marriott / San Francisco Marriott Marquis | Venue website | Venue existence and meeting-hosting suitability | Medium |
| Current-year attendee, exhibitor, sponsor, agenda, and speaker lists | Not verified in available materials | No confirmed counts or participant lists were established for this report | Low until official current-year materials are reviewed |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to FOCIS 2026 Annual Meeting — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.